我院门诊2012—2015年第二类精神药品使用分析
x

请在关注微信后,向客服人员索取文件

篇名: 我院门诊2012—2015年第二类精神药品使用分析
TITLE:
摘要: 目的:为第二类精神药品的临床合理使用提供参考。方法:回顾性分析我院门诊2012-2015年第二类精神药品处方,对常用药品的处方数,患者性别、年龄、临床诊断分布,使用频度(DDDs)和药物利用指数(DUI)等进行统计分析。结果:2012-2015年,我院门诊第二类精神药品占调查处方总量的25.09%;使用频率最高的药物是阿普唑仑片、氯硝西泮片、劳拉西泮片和艾司唑仑片,共占第二类精神药品处方总量的93.10%。使用第二类精神药品的男女性别比例为1 ∶ 1.50;19~35岁年龄段患者使用最多,占34.62%;精神分裂症患者处方比例最高,达45.17%。阿普唑仑DDDs最高,为742 141.67,其DUI为1.075;其他药品DUI均<1.0。结论:我院第二类精神药品使用基本合理,应继续严格执行《精神药品临床应用指导原则》,避免第二类精神药品的滥用现象。
ABSTRACT: OBJECTIVE: To provide reference for rational use of second class of psychotropic drugs in the clinic. METHODS: The second class of psychotropic drugs in outpatient department of our hospital during 2012-2015 were analyzed retrospectively in respects of the number of common drugs prescription, distribution of gender/age/disease diagnosis, DDDs and DUI, etc. RESULTS: During 2012-2015, second class of psychotropic drugs in outpatient department of our hospital accounted for 25.09% of total prescription amout. The drugs with high use frequency were alprazolam, clonazepam, lorazepam and estazolam, accounting for 93.10% of total prescription amount of second class of psychotropic drugs. The proportion of male to female was 1 ∶ 1.50; the patients aged 19-35 years old took up the biggest proportion, accounting for 34.62%. The proportion of schizophrenia prescription was the highest, accounting for 45.17%. DDDs of alprazolam was the highest, being 742 141.67; its DUI was 1.075; DUI of other drugs was lower than 1.0. CONCLUSIONS: The use of second class of psychotropic drugs is basically reasonable in our hospital. Guiding principles of Clinical Application of Psychotropic Drugs should be implemented strictly and continously to avoid abuse of second class of psychotropic drugs.
期刊: 2016年第27卷第17期
作者: 张俊青,李荣琴,王年生,张龚
AUTHORS: ZHANG Junqing,LI Rongqin,WANG Niansheng,ZHANG Gong
关键字: 第二类精神药品;使用频度;药物利用指数;依赖性;用药分析
KEYWORDS: Second class of psychotropic drugs; DDD; DUI; Dependence; Analysis of drug use
阅读数: 404 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!